SS
Senthilkannan Sridevi
About Senthilkannan Sridevi
Data last updated:
Senthilkannan Sridevi is a Director at Biomics Pharmaceuticals Private Limited (since 2012). The companies operate in Pharma. Biomics Pharmaceuticals Private Limited reported revenue of ₹2.53 Cr (FY 2025). Earlier, Senthilkannan Sridevi was a Director at Neo 4M Private Limited (from 2012).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Biomics Pharmaceuticals Private Limited U52310TN2012PTC083879 | Director | 05 Jan 2012 | 2012 | ₹2.53 Cr (FY 2025) | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Neo 4M Private Limited U52300TN2012PTC084077 | Director | 20 Jan 2012 | 2012 | ₹27,000 (FY 2016) | Strike Off |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Senthilkannan Sridevi
| Name | DIN | Company | Designation |
|---|---|---|---|
| Ramalingam Senthilkannan | 05109231 | Biomics Pharmaceuticals Private Limited | Managing Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Senthilkannan Sridevi
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Senthilkannan Sridevi
Senthilkannan Sridevi currently holds 1 directorship: Biomics Pharmaceuticals Private Limited (Director, since 05 Jan 2012, revenue ₹2.53 Cr (FY 2025)).
Senthilkannan Sridevi was first appointed on 05 Jan 2012 as Director at Biomics Pharmaceuticals Private Limited.
Senthilkannan Sridevi held 1 earlier board appointment: Neo 4M Private Limited (Director, from 20 Jan 2012).
The current boards of Senthilkannan Sridevi's companies include Ramalingam Senthilkannan (Biomics Pharmaceuticals Private Limited).